We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

688469:SSEUnited Nova Technology Co. Ltd. Class A Analysis

Data as of 2026-06-01 - not real-time

CN¥7.67

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

United Nova Technology is trading at CNY 7.67, just below its 20‑day SMA of 7.72 but comfortably above the 50‑day (7.03) and 200‑day (6.93) averages, indicating short‑term pressure yet a longer‑term bullish backdrop. The MACD line (0.345) sits marginally above its signal (0.337) and the histogram is positive, while RSI is neutral at 50.7 and volume is increasing, all pointing to a technically supportive environment.
Fundamentally, the picture is starkly different: the company posts negative gross (‑5.9%) and operating margins (‑4.4%), a trailing EPS of ‑0.06, and a forward PE of ‑76.7, reflecting loss‑making operations. Debt (CNY 12.14 bn) dwarfs cash (CNY 4.85 bn) with a debt‑to‑equity of 67%, and free cash flow is negative. The DCF‑derived fair value of CNY 3.26 is less than half the current price, suggesting significant overvaluation. Volatility is high at 63% over the past 30 days, though beta is near zero, indicating limited market‑wide systematic risk. No dividend is paid, removing any yield cushion.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 5/10

Key Factors

  • Price near short‑term support but below 20‑day SMA
  • Technical bullish signals (MACD, volume) are modest
  • Negative earnings and cash flow limit upside

Medium Term

1–3 years
Positive
Model confidence: 7/10

Key Factors

  • Revenue growth of 13% suggests potential top‑line recovery
  • Improving technical trend (price above 50‑day SMA)
  • Opportunity if the company can restructure debt and turn cash flow positive

Long Term

> 3 years
Cautious
Model confidence: 6/10

Key Factors

  • Persistent losses and high leverage raise solvency concerns
  • DCF fair value far below market price implies limited upside
  • High sector volatility and regulatory headwinds in China

Key Metrics & Analysis

Financial Health

Revenue Growth13.20%
Profit Margin-5.96%
P/E Ratio-76.7
ROE-8.85%
ROA-3.05%
Debt/Equity67.15
P/B Ratio5.2
Op. Cash FlowCN¥2.2B
Free Cash FlowCN¥-1593912320
Industry P/E43.0

Technical Analysis

TrendBullish
RSI50.7
SupportCN¥6.72
ResistanceCN¥9.12
MA 20CN¥7.72
MA 50CN¥7.03
MA 200CN¥6.93
MACDBullish
VolumeIncreasing
Fear & Greed Index93.25

Valuation

Fair ValueCN¥3.26
GradeOvervalued
TypeValue

Risk Assessment

Beta-0.02
Volatility63.30%
Sector RiskHigh
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.